# Personalis (NeXT Personal)
> Personalis is a cancer genomics company that provides advanced genomic sequencing and analytics for precision medicine. Its flagship NeXT Platform, particularly NeXT Personal, is designed to detect minimal residual disease (MRD) with ultra-high sensitivity by identifying a personalized signature of up to 1,800 mutations in a patient's tumor.
- URL: https://optimly.ai/brand/personalis-next-personal
- Slug: personalis-next-personal
- BAI Score: 72/100
- Archetype: Challenger
- Category: Biotechnology
- Last Analyzed: April 10, 2026
## Competitors
- Adaptive Biotechnologies (https://optimly.ai/brand/adaptive-biotechnologies)
- Foundation Medicine (https://optimly.ai/brand/foundation-medicine)
- Natera (Signatera) (https://optimly.ai/brand/natera-signatera)
## Buyer Intent Signals
Problems: Standard Pathology Monitoring: Hospital pathology departments manually performing tissue staining and analysis without personalized longitudinal monitoring. | Clinical Research Agencies: Hiring specialized clinical research organizations to manage patient monitoring data manually.
Solutions: ultra-sensitive MRD testing oncology | tumor-informed liquid biopsy companies | whole genome cancer recurrence monitoring | NeXT personal clinical trial results | best test for early cancer recurrence detection | Adjacent Screening Tools: Utilizing liquid biopsy tools designed for early detection (e.g., GRAIL) rather than post-diagnosis recurrence monitoring.